Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.

Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Hurwitz RL, Lau CC, Chintagumpala M, Blaney SM, Li XN.

Neuro Oncol. 2013 Sep;15(9):1173-85. doi: 10.1093/neuonc/not065. Epub 2013 May 7.

2.

Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.

Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM.

J Gen Virol. 2012 Dec;93(Pt 12):2606-13. doi: 10.1099/vir.0.046011-0. Epub 2012 Sep 12.

PMID:
22971818
3.

Structural features of the Seneca Valley virus internal ribosome entry site (IRES) element: a picornavirus with a pestivirus-like IRES.

Willcocks MM, Locker N, Gomwalk Z, Royall E, Bakhshesh M, Belsham GJ, Idamakanti N, Burroughs KD, Reddy PS, Hallenbeck PL, Roberts LO.

J Virol. 2011 May;85(9):4452-61. doi: 10.1128/JVI.01107-10. Epub 2011 Feb 16.

4.

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL.

Clin Cancer Res. 2011 Feb 15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8.

5.

A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN.

Neuro Oncol. 2011 Jan;13(1):14-27. doi: 10.1093/neuonc/noq148. Epub 2010 Nov 12.

6.

Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.

Venkataraman S, Reddy SP, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS.

Structure. 2008 Oct 8;16(10):1555-61. doi: 10.1016/j.str.2008.07.013.

7.

Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus.

Hales LM, Knowles NJ, Reddy PS, Xu L, Hay C, Hallenbeck PL.

J Gen Virol. 2008 May;89(Pt 5):1265-75. doi: 10.1099/vir.0.83570-0.

PMID:
18420805
8.

Crystallization and preliminary X-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family.

Venkataraman S, Reddy SP, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Apr 1;64(Pt 4):293-6. doi: 10.1107/S1744309108006921. Epub 2008 Mar 21.

9.

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.

Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL.

J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. Epub 2007 Oct 30.

10.

Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.

Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM, Ganesh S, Hay C, Huang Y, Kaloss M, Marinov A, Phipps SS, Reddy PS, Shirley PS, Skripchenko Y, Xu L, Yang J, Forry-Schaudies S, Hallenbeck PL.

Cancer Gene Ther. 2004 Aug;11(8):555-69.

PMID:
15232601
11.

An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.

Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.

Cancer Res. 2003 Apr 1;63(7):1490-9.

12.

Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob.

Hay CM, De Leon H, Jafari JD, Jakubczak JL, Mech CA, Hallenbeck PL, Powell SK, Liau G, Stevenson SC.

J Vasc Res. 2001 Jul-Aug;38(4):315-23.

PMID:
11455202
13.

Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells.

Jakubczak JL, Rollence ML, Stewart DA, Jafari JD, Von Seggern DJ, Nemerow GR, Stevenson SC, Hallenbeck PL.

J Virol. 2001 Mar;75(6):2972-81.

14.

Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin.

Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL.

Hum Gene Ther. 2000 Sep 20;11(14):1983-96.

PMID:
11020798
15.

Targetable gene delivery vectors.

Hallenbeck PL, Stevenson SC.

Adv Exp Med Biol. 2000;465:37-46. Review.

PMID:
10810613
16.

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.

Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, Phipps S, Chiang YL.

Hum Gene Ther. 1999 Jul 1;10(10):1721-33.

PMID:
10428217
17.

Differential 9-cis-retinoic acid-dependent transcriptional activation by murine retinoid X receptor alpha (RXR alpha) and RXR beta. Role of cell type and RXR domains.

Hallenbeck PL, Minucci S, Lippoldt R, Phyillaier M, Horn V, Ozato K, Nikodem VM.

J Biol Chem. 1996 May 3;271(18):10503-7.

18.
19.

DNA binding and heteromerization of the Drosophila transcription factor chorion factor 1/ultraspiracle.

Christianson AM, King DL, Hatzivassiliou E, Casas JE, Hallenbeck PL, Nikodem VM, Mitsialis SA, Kafatos FC.

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11503-7.

20.

Heterodimerization of thyroid hormone (TH) receptor with H-2RIIBP (RXR beta) enhances DNA binding and TH-dependent transcriptional activation.

Hallenbeck PL, Marks MS, Lippoldt RE, Ozato K, Nikodem VM.

Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5572-6.

21.
22.

Supplemental Content

Loading ...
Support Center